French drug maker Sanofi reports positive vaccine results
28 September 2021 - 09:50
by Sudip Kar-Gupta
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Paris — Sanofi on Tuesday announced positive interim results from its early-stage study for the mRNA-based Covid-19 vaccine candidate it is developing with Translate Bio, a boost for the French drug company after delays with its other shot.
Sanofi said phase one and two data from these results showed neutralising antibody seroconversion in 91%-100% of study participants, two weeks after a second injection, across all three dosages tested.
“These results will clearly help inform the path forward for our mRNA development programmes,” said Jean-Francois Toussaint, global head of research & development at Sanofi Pasteur.
No safety concerns were observed and the tolerability profile is comparable to that of other unmodified mRNA Covid-19 vaccines, the company said. Further data will be presented at a later date.
It did not say if these results will pave the way for the launch of late-stage human trials to test the shot’s efficacy, which, if positive, would be the final step before applying for regulatory approval.
Sanofi is under pressure to revive its drug pipeline and eager to overcome setbacks in the Covid-19 vaccine race. It said these results showed the potential behind the Translate Bio company it recently acquired.
The company is also testing a potential Covid-19 vaccine developed with Britain’s GlaxoSmithKline, but the progress of that shot was delayed after disappointing early results late last year.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
French drug maker Sanofi reports positive vaccine results
Paris — Sanofi on Tuesday announced positive interim results from its early-stage study for the mRNA-based Covid-19 vaccine candidate it is developing with Translate Bio, a boost for the French drug company after delays with its other shot.
Sanofi said phase one and two data from these results showed neutralising antibody seroconversion in 91%-100% of study participants, two weeks after a second injection, across all three dosages tested.
“These results will clearly help inform the path forward for our mRNA development programmes,” said Jean-Francois Toussaint, global head of research & development at Sanofi Pasteur.
No safety concerns were observed and the tolerability profile is comparable to that of other unmodified mRNA Covid-19 vaccines, the company said. Further data will be presented at a later date.
It did not say if these results will pave the way for the launch of late-stage human trials to test the shot’s efficacy, which, if positive, would be the final step before applying for regulatory approval.
Sanofi is under pressure to revive its drug pipeline and eager to overcome setbacks in the Covid-19 vaccine race. It said these results showed the potential behind the Translate Bio company it recently acquired.
The company is also testing a potential Covid-19 vaccine developed with Britain’s GlaxoSmithKline, but the progress of that shot was delayed after disappointing early results late last year.
Reuters
How to invest in the healthy future of vaccine stocks
Sanofi buys Kadmon, adding important transplant drug to range
A Covid booster shot in the foot for richer countries?
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Sanofi to buy Translate Bio in bid to use potential of mRNA in cancer and ...
Sanofi raises profit outlook after strong second quarter
PODCAST | State is doing its best with vaccine rollout despite problems, Ipasa ...
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.